Hypogonadism and Urologic Surgeries: a Narrative Review

Overview

Journal Transl Androl Urol

Date 2022 Aug 12

PMID 35958902

Authors

Kiarad Fendereski

Mohammad Ali Ghaed

Joshua K Calvert

James M Hotaling

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Previous studies indicated that the treatment of male hypogonadism can be beneficial for intraoperative and postsurgical outcomes. In this study, we aimed to determine the impact of male hypogonadism on urologic surgeries. We provided an overview of the key studies in the field with the focus on the outcomes of urologic surgeries in hypogonadal men with/without testosterone replacement therapy (TRT).

Methods: We performed a literature review in PubMed and Google Scholar databases for the most relevant articles pertaining to the outlined topics without placing any limitations on publication years or study designs. We included full-text English articles published in peer reviewed journals between January 1970 and March 2022.

Key Content And Findings: Androgen deficiency is a common finding after major urologic surgeries. Although guidelines recommend against TRT in men with prostate carcinoma, recent investigations showed no association between TRT and disease progression and recurrence. Indeed, recent evidence suggested that low androgen levels could be related to high grade prostate carcinoma and increased risk of upgrading from low to high grade disease. Investigations on the application of TRT in benign prostatic hyperplasia (BPH) patients also revealed contrasting results. While some studies suggested higher rates of prostate-related events in men who received TRT, others showed that TRT could alleviate urinary symptoms in hypogonadal men with BPH. Decreased testosterone level is commonly seen in bladder cancer patients. The treatment of perioperative androgen deficiency can reduce postoperative morbidities and lower the risk of recurrence in these patients. Low testosterone levels are observed in approximately half of the men who undergo artificial urinary sphincter (AUS) placement and can increase the risk of complications.

Conclusions: The role of testosterone treatment in patients with urologic diseases such as prostate carcinoma and BPH is controversial. Further investigations are needed to determine the impact of hypogonadism and TRT on the outcomes of urologic surgeries in patients with androgen deficiency.

Citing Articles

Artificial urinary sphincter and stricture disease: surgical principles in management.

Martins F, Bernal J, Tryfonyuk L, Holm H Transl Androl Urol. 2024; 13(8):1717-1728.

PMID: 39280683 PMC: 11399027. DOI: 10.21037/tau-23-16.

Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study.

Asanad K, Horns J, Driggs N, Samplaski M, Hotaling J Int J Impot Res. 2024; 36(6):655-658.

PMID: 38177194 DOI: 10.1038/s41443-023-00820-3.

References

Carrero J, Qureshi A, Nakashima A, Arver S, Parini P, Lindholm B . Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2010; 26(1):184-90. DOI: 10.1093/ndt/gfq397. View

Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, Allory Y . Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int. 2010; 107(9):1400-3. DOI: 10.1111/j.1464-410X.2010.09816.x. View

Bailey G, Linder B, Rivera M, Ziegelmann M, Rangel L, Elliott D . The impact of androgen deprivation on artificial urinary sphincter outcomes. Transl Androl Urol. 2016; 5(5):756-761. PMC: 5071185. DOI: 10.21037/tau.2016.06.07. View

Kawakami J, Cowan J, Elkin E, Latini D, DuChane J, Carroll P . Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006; 106(8):1708-14. DOI: 10.1002/cncr.21799. View

Trost L, Mulhall J . Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials. J Sex Med. 2016; 13(7):1029-46. PMC: 5516925. DOI: 10.1016/j.jsxm.2016.04.068. View

Haider A, Gooren L, Padungtod P, Saad F . Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia. 2009; 41(1):7-13. DOI: 10.1111/j.1439-0272.2008.00880.x. View

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Kalinchenko S, Vishnevskiy E, Koval A, Mskhalaya G, Saad F . Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male. 2008; 11(2):57-61. DOI: 10.1080/13685530801953994. View

Tenover J . Experience with testosterone replacement in the elderly. Mayo Clin Proc. 2000; 75 Suppl:S77-81; discussion S82. View

10.

Kim H, Hoon Kim B, Park C, Il Kim C . Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence. Korean J Urol. 2012; 53(1):9-13. PMC: 3272561. DOI: 10.4111/kju.2012.53.1.9. View

11.

Kaplan S, Meehan A, Shah A . The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol. 2006; 176(4 Pt 1):1524-7. DOI: 10.1016/j.juro.2006.06.003. View

12.

Marks L, Mazer N, Mostaghel E, Hess D, Dorey F, Epstein J . Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006; 296(19):2351-61. DOI: 10.1001/jama.296.19.2351. View

13.

Chen F, Langenstroer P, Zhang G, Iwamoto Y, See W . Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. J Urol. 2003; 170(5):2009-13. DOI: 10.1097/01.ju.0000092238.15685.10. View

14.

Schroeder E, Terk M, Sattler F . Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies. Am J Physiol Endocrinol Metab. 2003; 285(1):E16-24. DOI: 10.1152/ajpendo.00032.2003. View

15.

Abdel-Hamid A, Ali E . Effect of testosterone therapy on the urinary bladder in experimental hypogonadism of rats. J Mol Histol. 2015; 46(3):263-72. DOI: 10.1007/s10735-015-9617-4. View

16.

Kathrins M, Doersch K, Nimeh T, Canto A, Niederberger C, Seftel A . The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review. Urology. 2015; 88:22-32. DOI: 10.1016/j.urology.2015.11.006. View

17.

Haider K, Haider A, Doros G, Traish A . Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study. J Urol. 2017; 199(1):257-265. DOI: 10.1016/j.juro.2017.07.039. View

18.

Hofer M, Kapur P, Cordon B, Hamoun F, Russell D, Scott J . Low Testosterone Levels Result in Decreased Periurethral Vascularity via an Androgen Receptor-mediated Process: Pilot Study in Urethral Stricture Tissue. Urology. 2017; 105:175-180. DOI: 10.1016/j.urology.2017.02.037. View

19.

Reinhardt W, Kubber H, Dolff S, Benson S, Fuhrer D, Tan S . Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation. Endocrine. 2018; 60(1):159-166. DOI: 10.1007/s12020-018-1543-2. View

20.

Coward R, Simhan J, Carson 3rd C . Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int. 2009; 103(9):1179-83. DOI: 10.1111/j.1464-410X.2008.08240.x. View